![alret icon](https://deviserve.z10.web.core.windows.net/assets/images/alert.webp)
Data will be updated when it becomes available.
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
From March 28 to April 4, 2024, the US drug regulator conducted a normal current Good Manufacturing Practices (cGMP) inspection at the site.
Cipla stated in an exchange statement that this extra investment, made through a convertible loan, will accelerate the company's engagement in the mRNA space.
Lanreotide Injection is indicated for the treatment of patients with acromegaly and gastroenteropancreatic neuroendocrine tumors.
Cipla primarily develops drugs to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, etc.
On May 10, Cipla announced a 10% increase in revenue to ₹6,163 Crore and a 79% increase in fourth-quarter profit to ₹939 Crore.
The deal is anticipated to close within 60 days after the BTA's signature, or on a later date that the parties have mutually agreed upon in writing.
Recommendation: Add; Target price: Rs 1345
The corporation claimed "personal and family commitments" as the reason for her departure from her present post.
Its sales for the quarter increased 13.7% YoY to Rs 6,604 crore
An improper pouch seal may cause powder mix to leak outside the pouch
ATTENTION INVESTORS
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Risk Disclosure on Derivatives
Copyright © IIFL Securities Ltd. All rights Reserved.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
We are ISO 27001:2013 Certified.
This certificate demonstrates that IIFL as an organization has defined and put in place best-practice information security processes.